NCT06914635 Immunotherapy: Care and Prevention of Infectious and Tumoral Diseases (ImmunoHUB)
| NCT ID | NCT06914635 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
| Condition | SARS CoV-2 |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-05-30 |
| Primary Completion | 2025-02-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2023-05-30 with a primary completion date of 2025-02-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The project comprises two research lines. In the line 1, human monoclonal antibodies toward SARS-CoV-2 will be generate and characterized by in vitro functional tests. In the line 2, in vitro tests will be performed to evaluate the efficency of immune response mediated by antibodies direct to specific tumor molecules.
Eligibility Criteria
Inclusion Criteria: Line 1: - Age \>18 at time of signing informed consent form * Signed informed consent form Line 2: - Primery liver tumor * Age \>18 at time of signing informed consent form * Signed informed consent form Exclusion Criteria: Line 1: - Active or history of neoplastic malignancy * Active autoimmune disease ongoing treatment with immunosuppressive therapy * Evidence of positive HIV, HCV, HBV test * Diabetes * Failure to sign informed consent form Line 2: - Concomitant diseases with life expectancy of less than 12 months * Chronic autoimmune or inflammatory diseases * Treatment with atezolizumab, bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, checkpoint inhibitors and tyrosine kinase inhibitors or anti-VEGF therapies * Other extrahepatic neoplasms occurring or in the last 3 years except for tumors resected with curative intent and without evidence of relapse for \>3 years prior to signing informed consent and considered low risk of relapse * HIV infection * Failure to sign informed consent form
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06914635 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying SARS CoV-2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06914635 currently recruiting?
Yes, NCT06914635 is actively recruiting participants. Contact the research team at m.mondelli@smatteo.pv.it for enrollment information.
Where is the NCT06914635 trial being conducted?
This trial is being conducted at Pavia, Italy.
Who is sponsoring the NCT06914635 clinical trial?
NCT06914635 is sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. The trial plans to enroll 40 participants.